We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Parexel International Corporation today announced that it had entered into a joint venture arrangement with Synchron Research Services Private Limited, pursuant to which it purchased a majority stake in a newly formed entity called PAREXEL International Synchron Private Limited into which Synchron transferred its clinical trial business operations located in Bangalore.
Privately held French biotech company Innate Pharma on Monday said it has signed a deal with U.S.-based Schering-Plough Corp. (SGP) to in-license some assets for developing toll-like receptors, or TLRs, which can help activate the body's adaptive immune system.
Founded with a mission to protect and preserve the gift of sight, executives from the newly created Sirion Therapeutics, Inc. unveiled their new company today.
Shares of Neurocrine Biosciences Inc. sank to a new 52-week low Monday after one analyst said the stock was overpriced despite being off more than 75 percent so far this year.
Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has announced that ReceptoPharm has signed a letter of intent to be fully acquired by Nutra Pharma Corp.
The National Institute of Allergy and Infectious Diseases (NIAID), a branch of the NIH, has granted Vical accelerated access to $2.6 million in funding for further development of Vaxfectin, an avian
influenza vaccine being developed under a grant awarded to Vical in September 2005, the company said.
A senior FDA official's speech urging the agency to pull back from requiring risk management plans as a part of the drug approval process signals a major change in the FDA's thinking on drug safety, an industry observer says.